It is expected to treat squamous cell carcinoma of the head and neck. The anti-PD-1 antibody
Time of Update: 2019-10-19
MSD today announced that the European Drug Administration's Committee on human medicinal products (CHMP) recommended approval of two options of keytruda (anti PD-1 therapy of MSD
Objective remission rate 77.8%! Cornerstone pharmaceutical anti-PD-L1 in patients with esophageal squamous cell carcinoma positive data
Time of Update: 2019-09-20
Suzhou September 19, 2019 / Meitong news agency / -- Cornerstone Pharmaceutical (Suzhou) Co., Ltd
(hereinafter referred to as "cornerstone pharmaceutical" or "company
Cell culture bottle Selection Guide
Time of Update: 2019-07-03
Polyester caps are designed (when unscrewed) for use in open systems that require gas exchange.
Keji biological is pleased to obtain the clinical trial permission of GPC3 targeting car-t cells for the treatment of GPC3 positive solid tumors
Time of Update: 2019-01-29
January 28, 2019 / Meitong news agency / -- carsgen therapeutics, a R & D enterprise of car-t cell immunotherapy, today announced that the company is developing products
The combination of bavencio and inlyta has achieved positive results in the phase 3 clinical trial of advanced renal cell carcinoma
Time of Update: 2018-09-12
Today, Merck KGaA and Pfizer jointly announced that the combination therapy composed of bavencio (avelumab) and inlita (axitinib) significantly improved the progression free survival (PFS) of patients in the phase 3 clinical trial for advanced renal cell carcinoma (RCC) (
Scientists have found that acyclic vitamin A can selectively prevent cancer stem cells from producing new tumors
Time of Update: 2018-04-26
The team studied the transcriptome of cells exposed to acyclic vitamin A and found that they had low expression of MYCN compared with untreated cells, which is usually expressed in tumors and associated with poor prognosis.
The results showed that ensartinib was effective and well tolerated in patients with ALK positive non-small cell lung cancer
Time of Update: 2018-04-13
According to the data of phase I / II study released at the 2016 ESMO Conference ( most of the non-small cell lung cancer patients who have not used clozatinib are effective in the treatment of ensortinib.
Lok positive non-small cell lung cancer with diagnosis approved today
Time of Update: 2017-06-02
Source: Wuxi apptec 2017-06-02 today, Roche announced that the FDA of the United States has approved Ventana ALK (d5f3) CDX test kit as a concomitant diagnosis
Novartis zykadia is approved for first-line treatment of ALK positive non-small cell lung cancer
Time of Update: 2017-05-31
The first-line approval of zykadia for ALK positive metastatic NSCLC demonstrates our commitment to cancer patients.
PNAs: new simple protein has positive effect on cell function
Time of Update: 2015-09-14
Scientists at Yale University have developed simple new proteins, which have little chemical diversity, but still play an amazing role in cell function, making cells just like
Selection and application of ultrasonic cell breaker
Time of Update: 2013-11-28
In use, the ultrasonic generator circuit converts 50 / 60Hz power supply into 18-21khz high-frequency and high-voltage power, so a large amount of heat will be produced in the process of crushing, which is generally broken in the ice bath.
Xalkori is still not recommended for ALK positive non-small cell lung cancer by nice final guidelines
Time of Update: 2013-09-30
September 29, 2013 12:11 source: Ding Xiangyuan UK National Health and Medical Quality Standards Agency (NICE) released the final use guidance plan for xalkori, a Pfizer drug
The new nice draft guidelines do not recommend the use of clozatinib in the treatment of ALK positive non-small cell lung cancer
Time of Update: 2013-08-20
2013-08-19 source: Ding Xiangyuan, in the final draft of the new lung cancer medication guidelines issued by nice, does not recommend the use of crazotinib from Pfizer